UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer

Asian journal of andrology, 2018-05, Vol.20 (3), p.230-237

2018

Volltextzugriff (PDF)

Recent progress in treating advanced prostate cancer

Current opinion in oncology, 2020-05, Vol.32 (3), p.210-215

Gourdin, Theodore

2020

Volltextzugriff (PDF)

Highlighting recent progress in the treatment of men with advanced prostate cancer

Current opinion in oncology, 2024-05, Vol.36 (3), p.174-179

Gourdin, Theodore

2024

Volltextzugriff (PDF)

Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer

The Prostate, 2022-09, Vol.82 (13), p.1264-1272

2022

Volltextzugriff (PDF)

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer

Frontiers in oncology, 2024-02, Vol.13, p.1202277-1202277

2024

Volltextzugriff (PDF)

Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions

Current opinion in oncology, 2022-05, Vol.34 (3), p.228-233

Gourdin, Theodore

2022

Volltextzugriff (PDF)

Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal

Current opinion in oncology, 2021-05, Vol.33 (3), p.252-256

Gourdin, Theodore

2021

Volltextzugriff (PDF)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001246

2020

Volltextzugriff (PDF)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e005813

2023

Volltextzugriff (PDF)

Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future

Current opinion in oncology, 2019-05, Vol.31 (3), p.188-193

Gourdin, Theodore

2019

Volltextzugriff (PDF)

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

Leukemia & lymphoma, 2014-07, Vol.55 (7), p.1533-1537

2014

Volltextzugriff (PDF)

Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials

Journal of oncology pharmacy practice, 2020-06, Vol.26 (4), p.861-865

2020

Volltextzugriff (PDF)

Treatments and challenges in advanced prostate cancer

Current opinion in oncology, 2023-05, Vol.35 (3), p.200-205

2023

Volltextzugriff (PDF)

Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions

Current opinion in oncology, 2018-05, Vol.30 (3), p.159-164

Gourdin, Theodore

2018

Volltextzugriff (PDF)

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

Cancer, 2019-05, Vol.125 (9), p.1459-1469

2019

Volltextzugriff (PDF)

Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy

Seminars in oncology, 2018-06, Vol.45 (3), p.156-163

2018

Volltextzugriff (PDF)

Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma

Bladder cancer, 2021-01, Vol.7 (2), p.143-148

2021

Volltextzugriff (PDF)

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A291-A291

2020

Volltextzugriff (PDF)

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication

Cancer genetics, 2014-10, Vol.207 (10), p.467-473

2014

Volltextzugriff (PDF)

Serial ctDNA profiling in patients with metastatic prostate cancer undergoing treatment with radium-223

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17018-e17018

2021

Volltextzugriff (PDF)

Association of elevated serum CEA with visceral metastasis and distinctive circulating tumor DNA alterations in castrate-resistant prostate cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17023-e17023

2021

Volltextzugriff (PDF)

Association of immune related adverse events with improved progression-free survival in patients receiving anti-PD-1 / PD-L1 therapy irrespective of corticosteroid use

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15088-e15088

2018

Volltextzugriff (PDF)

Navigating the Landscape of Increased Cancer Survivorship: When Malignant Pain Transitions from Acute to Chronic (FR416)

Journal of pain and symptom management, 2019-02, Vol.57 (2), p.406-407

2019

Volltextzugriff (PDF)

Genomic profiling of metastatic prostate cancer through analysis of circulating tumor DNA (ctDNA)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.174-174

2016

Volltextzugriff (PDF)

A phase I study of the ceramide nanoliposome in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2024, Vol.93 (1), p.23-29

2024

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer

Recent progress in treating advanced prostate cancer

Highlighting recent progress in the treatment of men with advanced prostate cancer

Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer

Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions

Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials

Treatments and challenges in advanced prostate cancer

Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy

Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma

265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication

Serial ctDNA profiling in patients with metastatic prostate cancer undergoing treatment with radium-223

Association of elevated serum CEA with visceral metastasis and distinctive circulating tumor DNA alterations in castrate-resistant prostate cancer

Association of immune related adverse events with improved progression-free survival in patients receiving anti-PD-1 / PD-L1 therapy irrespective of corticosteroid use

Navigating the Landscape of Increased Cancer Survivorship: When Malignant Pain Transitions from Acute to Chronic (FR416)

Genomic profiling of metastatic prostate cancer through analysis of circulating tumor DNA (ctDNA)

A phase I study of the ceramide nanoliposome in patients with advanced solid tumors

Suchergebnisse filtern